XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 26.87

+1.3%

Feb 3 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Thomas J Pittman who wrote (11326)	8/17/1999 12:57:00 PM
From: aknahow	Read Replies (1) of 17367

Changing endpoints after a trial has begun is not cool. Or after a P III is over and discovering your drug worked for something that you had not considered as an endpoint at the start of the trial also is apt to get a company no where. But in this case the FDA approved the change. But as I have posted and provided a link to it in a sepsis trial combining the endpoints does not make approval easier it apparently makes it more difficult to establish statistical significance for either morbidity or mortality. Again I do not know why. So from this point of view the FDA would not have been giving XOMA a freebe or a pass. I am o.k. with the change in endpoints but think the question was legitimate since changes in endpoints need to be explained.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next